Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Zhang, Jingxiao ^a   Li, Yan ^a   Chen, Xuetong ^b   Pan, Yanqiu ^a   Zhang, Shuwei ^a   Wang, Yonghua ^b  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b NORTHWEST A F UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACACETIN; CAFFEIC ACID; CRYPTOTANSHINONE; EPHEDRA EXTRACT; EPICATECHIN; ERIGERON BREVISCAPUS EXTRACT; FERULIC ACID; FREE RADICAL; GASTRODIA ELATA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GINSENOSIDE; HIRSUTEINE; KAEMPFEROL; LIGUSTICUM CHUANXIONG EXTRACT; LIGUSTILIDE; LIPID; NARINGENIN; PANAX NOTOGINSENG EXTRACT; PLANT EXTRACT; QUERCETIN; SALVIA MILTIORRHIZA EXTRACT; SALVIANOLIC ACID B; SCUTELLARIA BAICALENSIS EXTRACT; SCUTELLARIN; TANSHINONE I; TANSHINONE IIA; UNCARIA RHYNCHOPHYLLA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLIC ACID; PLANT MEDICINAL PRODUCT;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; COMPUTER MODEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EPHEDRA; ERIGERON BREVISCAPUS; GASTRODIA ELATA; GINKGO BILOBA; GINSENG; HERBAL MEDICINE; HUMAN; INHIBITION KINETICS; LIGUSTICUM CHUANXIONG; LIPID LOWERING ACTIVITY; LIPOPHILICITY; NERVE CELL; NEUROPROTECTION; PANAX NOTOGINSENG; RECURRENCE RISK; RISK REDUCTION; SALVIA MILTIORRHIZA; SCUTELLARIA BAICALENSIS; SYSTEM ANALYSIS; SYSTEMATIC REVIEW; SYSTEMS BIOLOGY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNCARIA; UNCARIA RHYNCHOPHYLLA; VASODILATATION; CACO 2 CELL LINE; DRUG DATABASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; MEDICINAL PLANT; MOLECULARLY TARGETED THERAPY; PHARMACOLOGY; PROCEDURES; STROKE;

CACO-2 CELLS; DATABASES, PHARMACEUTICAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; HERBAL MEDICINE; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACOLOGICAL PROCESSES; PLANT PREPARATIONS; PLANTS, MEDICINAL; SALVIA MILTIORRHIZA; SCUTELLARIA BAICALENSIS; STROKE; SYSTEMS BIOLOGY; UNCARIA;

EID: 84905460204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102506     Document Type: Article

References (77)

1. Mendis S, Puska P, Norrving B (2011) Global atlas on cardiovascular disease prevention and control: World Health Organization.
2. Gong X, Sucher NJ (1999) Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Trends in Pharmacological Sciences 20: 191-196.
3. Broussalis E, Killer M, McCoy M, Harrer A, Trinka E, et al. (2012) Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discovery Today 17: 296-309.
4. Mehta SL, Manhas N, Raghubir R (2007) Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Research Reviews 54: 34-66. (Pubitemid 46498164)
5. O'Collins VE, Macleod MR, Donnan GA, Howells DW (2012) Evaluation of combination therapy in animal models of cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 32: 585-597.
6. Lo EH, Dalkara T, Moskowitz MA (2003) Mechanisms, challenges and opportunities in stroke. Nature Reviews Neuroscience 4: 399-415. (Pubitemid 37280178)
7. Asahi M, Asahi K, Wang X, Lo EH (2000) Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. Journal of Cerebral Blood Flow & Metabolism 20: 452-457. (Pubitemid 30164888)
8. Sumii T, Lo EH (2002) Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33: 831-836. (Pubitemid 34204013)
9. Shuaib A, Yang Y, Nakada MT, Li Q, Yang T (2002) Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab′) 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. Journal of Cerebral Blood Flow & Metabolism 22: 215-222. (Pubitemid 34135652)
10. Feigin VL (2007) Herbal medicine in stroke: does it have a future? Stroke 38: 1734-1736.
11. Wu B, Liu M, Liu H, Li W, Tan S, et al. (2007) Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 38: 1973-1979.
12. Zhao S, Iyengar R (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annual Review of Pharmacology and Toxicology 52: 505-521.
13. Li X, Xu X, Wang J, Yu H, Wang X, et al. (2012) A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One 7: e43918.
14. Wang X, Xu X, Li Y, Li X, Tao W, et al. (2013) Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication. Integrative Biology 5: 351-371.
15. Huang C, Zheng C, Li Y, Wang Y, Lu A, et al. (2013) Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform.
16. Tavazoie S, Hughes JD, Campbell MJ, Cho RJ, Church GM (1999) Systematic determination of genetic network architecture. Nature Genetics 22: 281-285. (Pubitemid 29297256)
17. Hou T, Xu X (2002) ADME evaluation in drug discovery. 1. Applications of genetic algorithms to the prediction of blood-brain partitioning of a large set of drugs. J Mol Model 8: 337-349. (Pubitemid 37240060)
18. Wang J, Krudy G, Hou T, Zhang W, Holland G, et al. (2007) Development of reliable aqueous solubility models and their application in druglike analysis. Journal of Chemical Information and Modeling 47: 1395-1404. (Pubitemid 47210043)
19. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001) Estimation of aqueous solubility of chemical compounds using E-state indices. J Chem Inf Comput Sci 41: 1488-1493.
20. Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54: 355-366. (Pubitemid 34260958)
21. Arnott JA, Planey SL (2012) The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 7: 863-875.
22. Tetko IV, Bruneau P (2004) Application of ALOGPS to predict 1-octanol/water distribution coefficients, logP, and logD, of AstraZeneca in-house database. J Pharm Sci 93: 3103-3110. (Pubitemid 39657814)
23. Liu H, Wang J, Zhou W, Wang Y, Yang L (2013) Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice. J Ethnopharmacol 146: 773-793.
24. Xu X, Zhang W, Huang C, Li Y, Yu H, et al. (2012) A novel chemometric method for the prediction of human oral bioavailability. International journal of molecular sciences 13: 6964-6982.
25. Pang KS (2003) Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 31: 1507-1519.
26. González-Álvarez I, Bermejo M, Mangas Sanjuan V, Centelles I, Garrigues TM, et al. (2011) In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach. Molecular Informatics 30: 376-385.
27. Li L, Li Y, Wang Y, Zhang S, Yang L (2007) Prediction of human intestinal absorption based on molecular indices. Journal of molecular science 23: 286-291.
28. Kam A, Li KM, Razmovski-Naumovski V, Nammi S, Chan K, et al. (2012) The protective effects of natural products on blood-brain barrier breakdown. Curr Med Chem 19: 1830-1845.
29. Li L, Li Y, Wang Y, Zhang S (2007) Prediction of BBB permeation based on molecular indices. Chinese journal of medicinal chemistry 17: 221-228.
30. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136.
31. Ye H, Ye L, Kang H, Zhang D, Tao L, et al. (2011) HIT: linking herbal active ingredients to targets. Nucleic Acids Res 39: D1055-1059.
32. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206. (Pubitemid 46227119)
33. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, et al. (2012) STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 40: D876-880.
34. Yu H, Chen J, Xu X, Li Y, Zhao H, et al. (2012) A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 7: e37608.
35. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al. (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92: 414-417.
36. Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology 267: 727-748. (Pubitemid 27170693)
37. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
38. Lin TH, Hsieh CL (2010) Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction. Chinese Medicine 5: 22.
39. Zeng X, Liu M, Yang Y, Li Y, Asplund K (2005) Ginkgo biloba for acute ischaemic stroke. Cochrane Database Syst Rev: CD003691.
40. Wu B, Liu M, Zhang S (2004) Dan Shen agents for acute ischaemic stroke. Cochrane Database Syst Rev: CD004295.
41. Zhou J, Zhou S (2010) Antihypertensive and neuroprotective activities of rhynchophylline: the role of rhynchophylline in neurotransmission and ion channel activity. J Ethnopharmacol 132: 15-27.
42. Zhou JY, Zhou SW (2012) Isorhynchophylline: A plant alkaloid with therapeutic potential for cardiovascular and central nervous system diseases. Fitoterapia 83: 617-626.
43. Chen CX, Jin RM, Li YK, Zhong J, Yue L, et al. (1992) Inhibitory effect of rhynchophylline on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao 13: 126-130.
44. Suk K, Kim SY, Leem K, Kim YO, Park SY, et al. (2002) Neuroprotection by methanol extract of Uncaria rhynchophylla against global cerebral ischemia in rats. Life Sci 70: 2467-2480. (Pubitemid 34267036)
45. Shi JS, Yu JX, Chen XP, Xu RX (2003) Pharmacological actions of Uncaria alkaloids, rhynchophylline and isorhynchophylline. Acta Pharmacol Sin 24: 97-101.
46. Lee S, Kim DH, Lee DH, Jeon SJ, Lee CH, et al. (2010) Oroxylin A, a flavonoid, stimulates adult neurogenesis in the hippocampal dentate gyrus region of mice. Neurochem Res 35: 1725-1732.
47. Jeon SJ, Rhee SY, Seo JE, Bak HR, Lee SH, et al. (2011) Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture. Neuroscience Research 69: 214-222.
48. Ha SK, Moon E, Lee P, Ryu JH, Oh MS, et al. (2012) Acacetin attenuates neuroinflammation via regulation the response to LPS stimuli in vitro and in vivo. Neurochem Res 37: 1560-1567.
49. Chang CP, Huang WT, Cheng BC, Hsu CC, Lin MT (2007) The flavonoid baicalin protects against cerebrovascular dysfunction and brain inflammation in experimental heatstroke. Neuropharmacology 52: 1024-1033.
50. Zhang F, Zheng W, Pi R, Mei Z, Bao Y, et al. (2009) Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Experimental Brain Research 193: 109-118.
51. Kim EJ, Jung SN, Son KH, Kim SR, Ha TY, et al. (2007) Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. Molecular Pharmacology 72: 62-72.
52. Suh SJ, Jin UH, Choi HJ, Chang HW, Son JK, et al. (2006) Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-alpha-induced matrix metalloproteinase-9 production and HASMC migration via downregulated NF-kappaB and AP-1. Biochem Pharmacol 72: 1680-1689. (Pubitemid 44765003)
53. Jin DZ, Yin LL, Ji XQ, Zhu XZ (2006) Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur J Pharmacol 549: 166-172.
54. Wang X, Morris-Natschke SL, Lee KH (2007) New developments in the chemistry and biology of the bioactive constituents of Tanshen. Medicinal Research Reviews 27: 133-148. (Pubitemid 44975189)
55. Chen YH, Du GH, Zhang JT (2000) Salvianolic acid B protects brain against injuries caused by ischemia-reperfusion in rats. Acta Pharmacol Sin 21: 463-466.
56. Li M, Zhao C, Wong RN, Goto S, Wang Z, et al. (2004) Inhibition of shear-induced platelet aggregation in rat by tetramethylpyrazine and salvianolic acid B. Clinical Hemorheology and Microcirculation. 31: 97-103. (Pubitemid 39273876)
57. O K, Lynn EG, Vazhappilly R, Au-Yeung KK, Zhu DY, et al. (2001) Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci 68: 903-912.
58. Gao DY, Han LM, Zhang LH, Fang XL, Wang JX (2009) Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs. Arch Pharm Res 32: 773-779.
59. Choi MY, Song HS, Hur HS, Sim SS (2008) Whitening activity of luteolin related to the inhibition of cAMP pathway in alpha-MSH-stimulated B16 melanoma cells. Arch Pharm Res 31: 1166-1171.
60. Kawai M, Hirano T, Higa S, Arimitsu J, Maruta M, et al. (2007) Flavonoids and related compounds as anti-allergic substances. Allergology International 56: 113-123. (Pubitemid 46984239)
61. Mueller M, Lukas B, Novak J, Simoncini T, Genazzani AR, et al. (2008) Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem 56: 11621-11630.
62. Culman J, Zhao Y, Gohlke P, Herdegen T (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28: 244-249. (Pubitemid 46661003)
63. Seibert K, Masferrer J, Zhang Y, Gregory S, Olson G, et al. (1995) Mediation of inflammation by cyclooxygenase-2. Agents and Actions Supplements 46: 41-50.
64. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, et al. (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 98: 1294-1299. (Pubitemid 32121226)
65. Di Napoli M, Papa F (2003) Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34: 2922-2929. (Pubitemid 37517770)
66. Anderson C (2003) Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key. Stroke 34: 1333-1334.
67. van Wijk SJ, Hageman GJ (2005) Poly(ADP-ribose) polymerase-1 mediated caspase-independent cell death after ischemia/reperfusion. Free Radic Biol Med 39: 81-90.
68. Geraets L, Moonen HJ, Brauers K, Wouters EF, Bast A, et al. (2007) Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells. J Nutr 137: 2190-2195. (Pubitemid 47529575)
69. Shi C, Liu J, Wu F, Yew DT (2010) Ginkgo biloba extract in Alzheimer's disease: From action mechanisms to medical practice. Int J Mol Sci 11: 107-123.
70. Kuo PL (2005) Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63. Life Sci 77: 2964-2976.
71. Iadecola C (1997) Bright and dark sides of nitric oxide in ischemic brain injury. Trends in Neurosciences 20: 132-139.
72. Meldrum BS (1995) Cytoprotective therapies in stroke. Current Opinion in Neurology 8: 15-23.
73. Gong X, Sucher NJ (1999) Stroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and development. Trends Pharmacol Sci 20: 191-196.
74. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, et al. (2006) The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 20: 1185-1187.
75. Lu C, Liu L, Chen Y, Ha T, Kelley J, et al. (2011) TLR2 ligand induces protection against cerebral ischemia/reperfusion injury via activation of phosphoinositide 3-kinase/Akt signaling. Journal of Immunology 187: 1458-1466.
76. Liu CL, Xie LX, Li M, Durairajan SS, Goto S, et al. (2007) Salvianolic acid B inhibits hydrogen peroxide-induced endothelial cell apoptosis through regulating PI3K/Akt signaling. PLoS One 2: e1321.
77. Gim SA, Sung JH, Shah FA, Kim MO, Koh PO (2013) Ferulic acid regulates the AKT/GSK-3beta/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model. Lab Anim Res 29: 63-69.